Good Simulation Practice

Good Simulation Practice require in silico medicine to become less speculative, and increasingly translational, that is to say, immediately applicable and useful for clinical and industrial applications.

The book 𝗧𝗞𝘄ð—Ūð—ŋð—ą ð—šð—žð—žð—ą ð—Ķð—ķ𝗚𝘂ð—đð—Ū𝘁ð—ķ𝗞ð—ŧ ð—Ģð—ŋð—Ū𝗰𝘁ð—ķ𝗰ð—ē Published Open Access on Springer Nature 

InSilicoTrials is thrilled to announce the publication of “𝙏ð™Ī𝙎𝙖𝙧𝙙 𝙂ð™Īð™Īd 𝙎𝙞ð™Ēð™Šð™Ąð™–ð™Đ𝙞ð™Īð™Ģ 𝙋𝙧𝙖𝙘ð™Đ𝙞𝙘𝙚Best practices for the use of computational modelling & simulation in the regulatory process of biomedical products ” a crucial document guiding the use of simulation data & evidence in the regulatory process of biomedical products. 
This work is the culmination of a global collaboration among in silico experts, coordinated by the In Silico World consortium, with significant contributions from the Avicenna Alliance, VPH Institute, and FDA professionals. 
Published in open access by Springer Nature Group, the book is edited by Prof. Marco Viceconti and InSilicoTrials’ CEO Luca Emili, addressing the need for standardized practices within the in silico field. 
Our strong belief is anchored in the insightful foreword by Pras Pathmanathan from the Office of Science and Engineering Laboratories, Center for Devices and Radiological Health at the FDA, suggesting a future where these words manifest into reality “â€Ķ 𝘊ð˜ĩ 𝘊ð˜ī ð˜Đð˜°ð˜ąð˜Ķð˜Ĩ ð˜ĩð˜Đð˜Ēð˜ĩ ð˜ĩð˜Đ𝘊ð˜ī ð˜Ģ𝘰𝘰𝘎 ð˜ļ𝘊𝘭𝘭 ð˜īð˜ĩ𝘊ð˜Ūð˜ķ𝘭ð˜Ēð˜ĩð˜Ķ 𝘧ð˜ķð˜ģð˜ĩð˜Đð˜Ķð˜ģ ð˜Ī𝘰ð˜Ŋ𝘷ð˜Ķð˜ģð˜īð˜Ēð˜ĩ𝘊𝘰ð˜Ŋð˜ī ð˜Ēð˜Ū𝘰ð˜Ŋð˜Ļð˜īð˜ĩ ð˜Ē𝘭𝘭 ð˜īð˜ĩð˜Ē𝘎ð˜Ķð˜Đ𝘰𝘭ð˜Ĩð˜Ķð˜ģð˜ī ð˜Ēð˜Ŋð˜Ĩ ð˜ķ𝘭ð˜ĩ𝘊ð˜Ūð˜Ēð˜ĩð˜Ķ𝘭𝘚 ð˜Ī𝘰ð˜Ŋð˜ĩð˜ģ𝘊ð˜Ģð˜ķð˜ĩð˜Ķ ð˜ĩ𝘰 ð˜ĩð˜Đð˜Ķ ð˜Ĩð˜Ķ𝘷ð˜Ķð˜­ð˜°ð˜ąð˜Ūð˜Ķð˜Ŋð˜ĩ 𝘰𝘧 ð˜Ī𝘰ð˜Ūð˜Ūð˜ķð˜Ŋ𝘊ð˜ĩ𝘚ð˜Ēð˜Īð˜Īð˜Ķð˜ąð˜ĩð˜Ķð˜Ĩ 𝘎𝘰𝘰ð˜Ĩ 𝘚𝘊ð˜Ūð˜ķ𝘭ð˜Ēð˜ĩ𝘊𝘰ð˜Ŋ 𝘗ð˜ģð˜Ēð˜Īð˜ĩ𝘊ð˜Īð˜Ķ, ð˜Ģð˜ģ𝘊ð˜Ŋð˜Ļ𝘊ð˜Ŋð˜Ļ 𝘔&𝘚 𝘧𝘰ð˜ģ ð˜Ūð˜Ķð˜Ĩ𝘊ð˜Īð˜Ē𝘭 ð˜ąð˜ģ𝘰ð˜Ĩð˜ķð˜Īð˜ĩð˜ī ð˜ĩ𝘰 ð˜Ūð˜Ēð˜ĩð˜ķð˜ģ𝘊ð˜ĩ𝘚.” 

Chapters’ content: 

  1. Introduction 
  2. Theoretical Foundations of GSP 
  3. Model Development 
  4. Model Credibility 
  5. Possible Qualification Pathways for In Silico Methodologies 
  6. Possible Health Technology Assessment Pathways 
  7. Ethical Review of In Silico Methodologies 
  8. The Sponsor 
  9. The Investigator: modellers and analysts 

If you’re seeking more details or interested in exploring how this groundbreaking publication can enhance your biosimulation strategies, don’t hesitate to get in touch. Our InSilicoTrials experts are ready to assist you in understanding the implications of Good Simulation Practice (GSP) for your projects, illustrating best practices, and demonstrating use cases to maximize GSP’s benefits for your drug development endeavors.

Start simulating now